CytoDyn Inc. (CYDY)

OTCMKTS: CYDY · Delayed Price · USD
0.160
+0.001 (0.66%)
Feb 28, 2024, 1:04 PM EST - Market open
Market Cap 164.79M
Revenue (ttm) n/a
Net Income (ttm) -55.65M
Shares Out 986.06M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE 10.81
Dividend n/a
Ex-Dividend Date n/a
Volume 1,794,743
Open 0.164
Previous Close 0.159
Day's Range 0.158 - 0.164
52-Week Range 0.150 - 0.480
Beta 0.10
Analysts n/a
Price Target n/a
Earnings Date Jan 9, 2023

About CYDY

CytoDyn Inc., a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer. Its leronlimab is currently under phase 2 development for th... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Dr. Jacob P. Lalezari M.D.
Employees 12
Stock Exchange OTCMKTS
Ticker Symbol CYDY
Full Company Profile

Financial Performance

Financial Statements

News

CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma

VANCOUVER, Washington, Feb. 01, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...

27 days ago - GlobeNewsWire

CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO

VANCOUVER, Washington, Jan. 29, 2024 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...

4 weeks ago - GlobeNewsWire

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of CytoDyn Inc. (OTC: CYDY)

NEW YORK , Jan. 18, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating CytoDyn Inc. (OTC: CYDY) on behalf of the company's shareholders.  The investigation seeks to determ...

5 weeks ago - PRNewsWire

CytoDyn Announces Webcast to Provide Company Update

VANCOUVER, Washington, Dec. 07, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...

2 months ago - GlobeNewsWire

CytoDyn Appoints Jacob Lalezari M.D. as Interim CEO

VANCOUVER, Washington, Nov. 21, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...

3 months ago - GlobeNewsWire

November 2023 Letter to Shareholders

VANCOUVER, Washington, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Dear Shareholders, We write to provide an update on CytoDyn Inc. (“CytoDyn” or “Company”), and to thank you for your continued support of the C...

4 months ago - GlobeNewsWire

CytoDyn Announces Company Updates and Investment Community Update Webcast

Claim Filed in Former CRO Litigation for Damages Exceeding $100M Dr. Arman Returns from Medical Leave as SVP of Business Operations Webcast to be held Monday, July 24 th , 2023, at 1 PM PT / 4 PM ET V...

8 months ago - GlobeNewsWire

CytoDyn Announces President Takes Medical Leave of Absence

Antonio Migliarese assumes interim President role Dr. Melissa Palmer appointed interim Chief Medical Officer Dr. Salah Kivlighn joins CytoDyn as clinical and strategic advisor

9 months ago - GlobeNewsWire

CytoDyn to Hold Webcast to Provide a Company Update

VANCOUVER, Washington, April 05, 2023 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential f...

11 months ago - GlobeNewsWire

CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO

VANCOUVER, Washington, Dec. 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...

1 year ago - GlobeNewsWire

Former CytoDyn CEO and clinical trial associate indicted for defrauding investors

The U.S. Department of Justice will prosecute the former CEO of Vancouver, Wash.-based biotech company CytoDyn, Nader Pourhassan, and an associate for allegedly defrauding investors.

1 year ago - GeekWire

CytoDyn to Host R&D Update on Wednesday, December 7, 2022

VANCOUVER, Washington, Nov. 22, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...

1 year ago - GlobeNewsWire

CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues

Company to complete and submit responses to FDA clinical hold

1 year ago - GlobeNewsWire

CytoDyn Announces Appointment of Additional Directors with Industry Experience

Stephen Simes career public biotech company CEO and Ryan Dunlap CFO with public biotech company experience join Board

1 year ago - GlobeNewsWire

CytoDyn to Hold Webcast to Provide a Quarterly Company Update

VANCOUVER, Washington, Sept. 19, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential f...

1 year ago - GlobeNewsWire

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of CytoDyn Inc. - CYDY

New York, New York--(Newsfile Corp. - August 12, 2022) - Pomerantz LLP is investigating claims on behalf of investors of CytoDyn Inc. ("CytoDyn" or the "Company") (OTCQB: CYDY). Such investors are adv...

1 year ago - Newsfile Corp

CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm

NEW YORK--(BUSINESS WIRE)-- #Action--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against CytoDyn, Inc. (“CytoDyn” or the “Compan...

1 year ago - Business Wire

CytoDyn Appoints Cyrus Arman, Ph.D., MBA, as President

VANCOUVER, Washington, July 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential fo...

1 year ago - GlobeNewsWire

CytoDyn Highlights NIH Grant for HIV Functional Cure Preclinical Study of Gene Therapy Based on Leronlimab

$5 Million Grant Awarded to OHSU for Preclinical Research of One-time Injection of Gene Therapy Based on Leronlimab for Functional Cure of HIV

1 year ago - GlobeNewsWire

CytoDyn Announces Resolution of Legal Dispute with Former Chief Medical Officer

VANCOUVER, Washington, May 23, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for...

1 year ago - GlobeNewsWire

CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor

VANCOUVER, Washington, May 13, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a biotechnology company developing leronlimab, a CCR5 antagonist with the potential for...

1 year ago - GlobeNewsWire

CytoDyn Announces Publication of Peer-Reviewed Paper, “Suppression of Human and Simian Immunodeficiency Virus Replication with the CCR5-Specific Antibody Leronlimab in Two Species”

VANCOUVER, Washington, April 12, 2022 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the ...

2 years ago - GlobeNewsWire

CytoDyn Announces Partial Clinical Hold of HIV Program and Full Clinical Hold of COVID-19 Program

Live webcast to be held March 31 discussing announcement

2 years ago - GlobeNewsWire

CytoDyn to Hold Webcast to Provide Company Update

VANCOUVER, Washington, March 30, 2022 (GLOBE NEWSWIRE) --  CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the...

2 years ago - GlobeNewsWire

CytoDyn's stock falls 4% after getting warning letter from FDA about experimental COVID-19 treatment

Shares of CytoDyn Inc. CYDY, -4.11% fell 4.9% in trading on Tuesday, the same day that the Food and Drug Administration issued a warning letter to the company over a video that features the former CEO...

2 years ago - Market Watch